Below Expected Sales for AMDS Hurt Artivion (AORT) in Q2

2 months ago 44

Soumya Eswaran

Tue, July 21, 2026 astatine 8:28 AM CDT 3 min read

Fred Alger Management, an concern absorption company, released its "Alger Weatherbie Specialized Growth Fund" second-quarter 2026 capitalist letter. A transcript of the missive tin beryllium downloaded here. U.S. equities experienced a beardown betterment successful Q2 2026, with the S&P 500 Index gaining 15.2%, marking its champion 4th since 2020. A ceasefire betwixt the United States and Iran and accelerated concern successful artificial quality (AI) regained marketplace optimism successful the quarter, starring the Information Technology and Industrials sectors upward, and Energy and Utilities lagged due to the fact that of falling lipid and state prices. In June, the Federal Reserve maintained dependable involvement rates, but the gathering had a hawkish tone. As AI transitions into its agentic phase, opportunities are identified wrong sectors adopting the technology. The Weatherbie Specialized Growth Fund's Class A shares outperformed the Russell 2500 Growth Index successful the quarter. The Industrials and Information Technology sectors contributed to the comparative performance, whereas Financials and Consumer Discretionary sectors detracted. In addition, delight cheque the Fund's apical 5 holdings to cognize its champion picks successful 2026.

In its Q2 2026 capitalist letter, Alger Weatherbie Specialized Growth Fund highlighted Artivion, Inc. (NYSE:AORT). Artivion, Inc. (NYSE:AORT) is simply a planetary shaper and distributor of aesculapian devices and implantable quality tissues. On July 20, 2026, Artivion, Inc. (NYSE:AORT) closed astatine $25.37 per share. One-month instrumentality of Artivion, Inc. (NYSE:AORT) was 22.68%, and its shares mislaid 16.55% implicit the past 52 weeks. Artivion, Inc. (NYSE:AORT) has a marketplace capitalization of $1.23 billion.

Alger Weatherbie Specialized Growth Fund stated the pursuing regarding Artivion, Inc. (NYSE:AORT) successful its Q2 2026 capitalist update:

"Artivion, Inc. (NYSE:AORT) manufactures, processes, and distributes aesculapian devices and implantable quality tissues utilized successful cardiac and vascular surgical procedures, with a absorption connected treating patients with aortic disease. The company's portfolio includes established products arsenic good arsenic newer technologies designed to amended outcomes successful analyzable cardiovascular procedures. During the quarter, shares detracted from show aft the institution reported in-line first-quarter results but modestly lowered its full-year outlook, chiefly owed to slower-than-expected starter acceptable income for AMDS, its cardinal caller merchandise cycle."

Is Artivion, Inc. (AORT) Among Billionaire Joseph Edelman's Long-Term Stock Picks?

Artivion, Inc. (NYSE:AORT) is not connected our database of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 28 hedge money portfolios held Artivion, Inc. (NYSE:AORT) astatine the extremity of the archetypal quarter, up from 25 successful the erstwhile quarter. Artivion, Inc. (NYSE:AORT) delivered full gross of $116.3 cardinal successful Q1 2026, an summation of 12% connected a non-GAAP changeless currency basis. While we admit the imaginable of Artivion, Inc. (NYSE:AORT) arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

Read Entire Article